Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1
Tomoki Maekawa, Hikaru Tamura, Hisanori Domon, Takumi Hiyoshi, Toshihito Isono, Daisuke Yonezawa, Naoki Hayashi, Naoki Takahashi, Koichi Tabeta, Takeyasu Maeda, Masataka Oda, Athanasios Ziogas, Vasileia Ismini Alexaki, Triantafyllos Chavakis, Yutaka Terao, George Hajishengallis
Tomoki Maekawa, Hikaru Tamura, Hisanori Domon, Takumi Hiyoshi, Toshihito Isono, Daisuke Yonezawa, Naoki Hayashi, Naoki Takahashi, Koichi Tabeta, Takeyasu Maeda, Masataka Oda, Athanasios Ziogas, Vasileia Ismini Alexaki, Triantafyllos Chavakis, Yutaka Terao, George Hajishengallis
View: Text | PDF
Research Article Immunology Inflammation

Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1

  • Text
  • PDF
Abstract

Macrolide antibiotics exert antiinflammatory effects; however, little is known regarding their immunomodulatory mechanisms. In this study, using 2 distinct mouse models of mucosal inflammatory disease (LPS-induced acute lung injury and ligature-induced periodontitis), we demonstrated that the antiinflammatory action of erythromycin (ERM) is mediated through upregulation of the secreted homeostatic protein developmental endothelial locus-1 (DEL-1). Consistent with the anti–neutrophil recruitment action of endothelial cell–derived DEL-1, ERM inhibited neutrophil infiltration in the lungs and the periodontium in a DEL-1–dependent manner. Whereas ERM (but not other antibiotics, such as josamycin and penicillin) protected against lethal pulmonary inflammation and inflammatory periodontal bone loss, these protective effects of ERM were abolished in Del1-deficient mice. By interacting with the growth hormone secretagogue receptor and activating JAK2 in human lung microvascular endothelial cells, ERM induced DEL-1 transcription that was mediated by MAPK p38 and was CCAAT/enhancer binding protein–β dependent. Moreover, ERM reversed IL-17–induced inhibition of DEL-1 transcription, in a manner that was dependent not only on JAK2 but also on PI3K/AKT signaling. Because DEL-1 levels are severely reduced in inflammatory conditions and with aging, the ability of ERM to upregulate DEL-1 may lead to a novel approach for the treatment of inflammatory and aging-related diseases.

Authors

Tomoki Maekawa, Hikaru Tamura, Hisanori Domon, Takumi Hiyoshi, Toshihito Isono, Daisuke Yonezawa, Naoki Hayashi, Naoki Takahashi, Koichi Tabeta, Takeyasu Maeda, Masataka Oda, Athanasios Ziogas, Vasileia Ismini Alexaki, Triantafyllos Chavakis, Yutaka Terao, George Hajishengallis

×

Figure 3

ERM improves mouse survival after LPS-induced acute lung injury in a manner comparable to that of DEL-1–Fc.

Options: View larger image (or click on image) Download as PowerPoint
ERM improves mouse survival after LPS-induced acute lung injury in a man...
(A) Experimental design. E. coli LPS (25 mg/kg; lethal dose) was administrated intratracheally. ERM, JSM, PC (all 3 antibiotics at 20 mg/kg), or ethanol control was administrated i.p., while DEL-1–Fc (10 μg) or Fc control (3.3 μg; equal molar amount with 10 μg DEL-1–Fc) was administered intravenously, at the indicated time points. (B) Survival rates for mice treated with ethanol control, ERM, JSM, or PC and subjected to acute lung injury by LPS (n = 14 mice/group). (C–E) Determination of TNF (C), IL-17 (D), and IL-10 (E) serum levels in LPS-challenged mice treated with ERM (or controls) or DEL-1–Fc (or Fc control); serum was collected 24 hours after LPS administration (n = 6 mice/group). (F) Survival rates of mice treated with DEL-1–Fc or Fc-control and subjected to acute lung injury by LPS (n = 14 mice/group). (G) Dynamics of oxygen saturation (SpO2) levels in mice subjected to LPS-induced acute lung injury over the course of 24 hours following LPS administration and treatment with the indicated antibiotics (left panel), DEL-1–Fc (right panel), or controls (ethanol or Fc) (n = 10 mice/group). (H and I) WT and Del1–/– mice were challenged with LPS and treated with ERM (or ethanol control) or DEL-1–Fc (or Fc control) as outlined in panel A. Neutrophil numbers were calculated in the BALF of WT and Del1–/– mice 24 hours after LPS administration (n = 10 mice/group) (H). Survival rate of WT and Del1–/– mice subjected to LPS-induced acute lung injury (n = 14 mice/group) (I). (J–L) Serum levels of TNF (J), IL-17 (K), and IL-10 (L) in LPS-challenged WT and Del1–/– mice treated with ERM (or ethanol control) or DEL-1–Fc (or Fc control); serum was collected 24 hours after LPS administration (n = 6 mice/group). (M) Survival rate of LPS-challenged Del1–/– mice treated with ERM (or ethanol control) or DEL-1–Fc (or Fc control) (n = 14 mice/group). Data are presented as the mean ± SD. **P < 0.01 by the log-rank test (B, F, I, and M). **P < 0.01, ***P < 0.001 by 1-way ANOVA followed by Tukey’s multiple comparisons test (C, D, E, H, J, K, and L). ***P < 0.001 by 2-way ANOVA followed by Holm-Šidák multiple comparisons test (G).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts